ȸ α â


α ޴

!  å

  •  (2)
  • (2)
    忬,ä | ̾(CIR)
 󼼺
SARS-CoV-2 : ڷγ-19 ̷ ȯ ӻ , ǥȭ


SMART
 

SARS-CoV-2 : ڷγ-19 ̷ ȯ ӻ , ǥȭ

Joaquim Bosch-Barrera, Begona Martin-Castillo,Maria Buxo, Joan Brunet , Jose Antonio Encina |

Ⱓ
2020-07-12
PDF
뷮
10 M
PC
Ȳ
1, 1, 0
 Ұ
ټ

 Ұ

COVID-19, the illness caused by infection with the novel coronavirus
SARS-CoV-2, is a rapidly spreading global pandemic in urgent need of eective
treatments. Here we present a comprehensive examination of the host- and
virus-targeted functions of the flavonolignan silibinin, a potential drug candidate
against COVID-19/SARS-CoV-2. As a direct inhibitor of STAT3?a master
checkpoint regulator of inflammatory cytokine signaling and immune response?
silibinin might be expected to phenotypically integrate the mechanisms of action of
IL-6-targeted monoclonal antibodies and pan-JAK1/2 inhibitors to limit the
cytokine storm and T-cell lymphopenia in the clinical setting of severe COVID-19.
As a computationally predicted, remdesivir-like inhibitor of RNA-dependent RNA
polymerase (RdRp)?the central component of the replication/transcription
machinery of SARS-CoV-2?silibinin is expected to reduce viral load and impede
delayed interferon responses.
The dual ability of silibinin to target both the host cytokine storm and the virus
replication machinery provides a strong rationale for the clinical testing of silibinin
against the COVID-19 global public health emergency. A randomized, open-label,
phase II multicentric clinical trial (SIL-COVID19) will evaluate the therapeutic
ecacy of silibinin in the prevention of acute respiratory distress syndrome in
moderate-to-severe COVID-19-positive onco-hematological patients at the Catalan
Institute of Oncology in Catalonia, Spain.

1 ڷγ̷
1. ڷγ̷-19(Covid-19) 7
2. ڷγ̷ з Ư 9
3. ڷγ̷ ̰ 11
4. ڷγ̷ (Covid-19 Organization) 13
5. ڷγ19: ȯ濡 ĥ? 19
6. ġ(Therapeutical Method) 22

2
Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm
and Virus Replication Machinery for Clinical Management of COVID-19
Patients

1. Abstract 23
2. Introduction 23
3. Silibinin: From an Old Remedy to a Direct STAT3 Inhibitor 25
4. Silibinin and STAT3:Targeting the(Reactive)Cytokine Storm 29
5. Silibinin and the RNA-Dependent RNA Polymerase Complex:
Targeting Virus Replication 32
6. Silibinin and COVID-19: An Ongoing Clinical Trial 34
7. Silibinin and SARS-CoV-2: An Early-Intervention in Older
Individuals at Risk ofSevere COVID-19? 35
8. Conclusions 37
9. References 38

ټ

  • 10
  • 8
  • 6
  • 4
  • 2

(ѱ 300̳)
侲
Ʈ
 ۼ ۼ õ

ϵ ϴ.